Brief: Ultimovacs Says New UV1 Data Showa Enhanced Efficacy

Zelluna ASA

18/10/2022 07:04

Oct 18 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * REG-ULTIMOVACS ANNOUNCES NEW UV1 DATA SHOWING ENHANCED
EFFICACY
INCLUDING IN HARD-TO-TREAT CANCER PATIENTS, SUPPORTING BROAD
UTILITY
    * UV1-103 STUDY EVALUATES COMPANY'S UNIVERSAL CANCER
VACCINE, UV1,
IN COMBINATION WITH ANTI-PD-1 CHECKPOINT INHIBITOR
PEMBROLIZUMAB, AS FIRST-LINE TREATMENT IN 30 PATIENTS WITH
ADVANCED NON-RESECTABLE AND METASTATIC MALIGNANT MELANOMA

Source text for Eikon:  ID:nGNE8mTt5T 
Further company coverage:  ULTI.OL 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))